Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Self-management support education, Connection to Health Interactive Behavior Change Technology, Connection to Health plus Coaching (CTH+C); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 89 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: Insulin Pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 14 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Escondido, California • Palo Alto, California • Aurora, Colorado + 5 more

Conditions: Breast Cancer, Endometrial Cancer, Ovarian Cancer
Interventions: arzoxifene; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: INNO-206; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2405319, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Cypress, California • Tustin, California • DeLand, Florida + 4 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Fresno, California • La Mesa, California • Lancaster, California + 26 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Bevacizumab, Gemcitabine, Carboplatin; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
Interventions: Pazopanib, Ixabepilone; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin (porfimer sodium) & photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 6 Months to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: TZP-102, Placebo; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 8 more

Conditions: Type 2 Diabetes
Interventions: telehealth-based clinical pharmacy intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: CS-917, metformin hydrochloride, pioglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more

Conditions: Type 2 Diabetes
Interventions: Bromocriptine mesylate; Drug
Lead sponsor: VeroScience; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Diabetes Mellitus, Type 2, Osteoporosis
Interventions: Denosumab 60 mg/ml [Prolia], Placebo; Drug · Other
Lead sponsor: Mishaela Rubin; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: Online diabetes workshop observation and learning sessions; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Oakland, California • San Jose, California • Stanford, California

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Tumor collection; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Cancer, Breast Cancer, Ovarian Cancer
Interventions: Blood Collection, Patient Questionnaires; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma
Interventions: DCVax-Direct; Biological
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 2
States / cities: Orlando, Florida • Houston, Texas

Conditions: Solid Tumors
Interventions: JAB-30355; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Denver, Colorado • Lake Mary, Florida • St Louis, Missouri + 4 more

Conditions: Diabetic Foot Ulcers
Interventions: Santyl, Tegaderm Hydrogel; Drug
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy; Procedure
Lead sponsor: University Medical Center Nijmegen; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 11
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Tumor-associated Hyperinsulinism (Tumor HI)
Interventions: Ersodetug (9 mg/kg) + SOC; Drug
Lead sponsor: Rezolute; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Thyroid Eye Disease, TED
Interventions: focus groups and individual interviews as well as filling out questionnaires; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Comparing Strategies for Translating Self-management Support Into Primary Care

Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

A Study of LY2405319 in Participants With Type 2 Diabetes

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Rural Area Pharmacist Intervention for Diabetes

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

Doctors and Web-based Self-management Support Pilot Study

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Assessment of Paclitaxel-Induced Neuropathy

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Psychological Burden of Thyroid Eye Disease